Anemia Treatment Drugs Market By Type Of Anemia (Iron Deficiency Anemia, Thalassemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia, Pernicious Anemia), By Type Of Drug (Supplements, Antibiotics, Immunosuppresants, Bone Marrow Stimulants, Corticosteroids, Gene Therapy, Iron Chelating Agents) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Anemia treatment drugs market accounted for a market value of US$ 23,155.8 Mn in 2017 and projected to grow at a CAGR of 16.4% during the forecast period from 2018 to 2026. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of haemoglobin in the blood results in anemia. Anemia is caused also due to numerous nutritional and non-nutritional factors such as infectious disease including malaria, soil-transmitted- helminthiasis, hookworm, and tuberculosis). The World Health Organization (WHO) estimated that globally anemia prevalence averaged 56%, with geographical variations in Europe & Asia the prevalence is in a range from 35% to 75%.

"Sickle cell anemia market expected to grow at a significant rate in the coming years due to presence more than five molecules in clinical trials phase III owned by large pharmaceutical companies"

During the forecast period from 2018 to 2026, sickle cell anemia will grow at an exponential rate due to rising prevalence & awareness related to sickle cell anemia, and expected market entry of monoclonal antibodies and other biological drugs to treat sickle cell anemia efficiently. According to World Health Organization (WHO), it is estimated that 312,000 children will be born worldwide with sickle cell anemia annually. Globally, the greatest burden exists in Sub-Saharan Africa, where 75% of the world sickle cell disease occurs. However, the three major molecules targeting sickle cell anemia in clinical trial phase III are Rivipansel (Pfizer, Inc.), Voxelotor (Global Blood Therapeutics, Inc.) and GBT440 (Global Blood Therapeutics, Inc.). Thus, market approval of these drugs in the near future will assist the overall growth of sickle cell anemia treatment market.

"Asia Pacific expected to be the fastest growing region in the global anemia treatment drugs market with highest prevalence of anemic population, and increasing awareness related to the diagnosis & treatment of anemia"

During the forecast period from 2018 to 2026, Asia Pacific expected to grow significantly due to rising prevalence & awareness related to anemia, initiation of anemia awareness campaigns by government & non-government organizations, and developing economic & healthcare infrastructure. According to the Sickle Cell Disease Coalition (SCDC), in 2016 India set a world record for screening 7.5 million people for SCD in a single day with help of effective awareness campaigns carried out by both government & non-government organizations. The key development observed in Asia Pacific was associated with the improvement in screening, interventions, skilled healthcare providers, and accessibility for medicines. The strong drug pipeline for anemia treatment also considered as one of the key factors expected to assist the growth of Asia Pacific anemia treatment drugs market in the near future.

Historical & Forecast Period

The anemia treatment drugs market analyzed considering current market trends for base year 2017 and based on future trends CAGRs calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on anemia treatment drugs market provides detailed information related to market dynamics such as restraints, drivers, & opportunities along with global trends. The report provides broad summary of the global anemia treatment drugs market by segmenting the market based on anemia type, drug type, and geography. The objective of publishing this in-depth research report is to assist the industry stakeholders in carrying-out strategic decisions and implementation in the anemia treatment drugs market.

This report further describes the major qualitative assessment factors including key market trends, market drivers & restraints, to assist in better understanding of global anemia treatment drugs market. The major players analyzed based on their product offering, market strategies, recent developments, and business strength. The report also provides attractive investment proposition based on the exhaustive geographical research carried out based on PESTEL analysis. Major companies profiled in the report include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceutical, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc. among others.

Key questions answered in this report

• What are anemia treatment drugs and their applications in different types of anemia?
• Which type of anemia is largest segment in global anemia treatment drugs market?
• What are the recent market trends and growth opportunities for the companies operating in anemia treatment industry?
• Which are the most attractive markets geographically for anemia treatment technology?
• What is pipeline analysis and overall future scenario of anemia treatment drugs market?
• What is the competitive landscape of anemia treatment drugs market?